The pancreatic lipase (PNLIP) antibody is a crucial tool in studying the enzyme responsible for dietary fat digestion. PNLIP, encoded by the PNLIP gene, is a 50 kDa serine hydrolase secreted by pancreatic acinar cells. It hydrolyzes triglycerides into fatty acids and monoglycerides in the small intestine, aided by bile salts and colipase. Dysregulation of PNLIP is linked to pancreatic disorders such as chronic pancreatitis, cystic fibrosis, and pancreatic insufficiency. Antibodies targeting PNLIP are widely used in immunoassays (e.g., ELISA, Western blot) and immunohistochemistry to quantify enzyme levels, assess pancreatic function, and investigate pathologies. They help differentiate pancreatic exocrine insufficiency from other malabsorption conditions and are employed in diabetes research due to debated findings about PNLIP expression in pancreatic β-cells. Recent studies also explore their diagnostic potential in liquid biopsies for non-invasive pancreatic disease monitoring. Commercial PNLIP antibodies are typically raised in rabbits or mice against specific epitopes, requiring validation for cross-reactivity with homologous lipases (e.g., PNLIPRP1/2). Proper controls are essential given the enzyme's post-translational modifications and tissue-specific expression patterns.